Brainsway Ltd. (TASE:BRIN) will conduct human clinical trials of its Deep TMS transcranial magnetic stimulation device in the UK in partnership with the National Institute of Neurological Disorders and Stroke (NINDS), a branch of Britain’s National Institutes of Health (NIH), for the treatment of Blepharospasm (BSP) and Tourette’s syndrome.
